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SUMMARY 
Metoclopramide, a dopamine antagonist, stimulates aldosterone secretion in 
normal man. We studied the response of plasma aldosterone, plasma renin 
activity, cortisol, sodium, potassium and serum prolactin to a 10-mg intra- 
venous dose of metoclopramide in six dexamethasone suppressed patients with 
aldosteronism (four with adrenal adenoma, two with bilateral adrenal hyper- 
plasia) and in six dexamethasone suppressed normal male volunteers. All 
subjects were studied on an ad libitum sodium diet. Patients were supplemented 
with oral potassium prior to study. 
Sodium and potassium were not different between groups and did not change 
following metoclopramide. Cortisol was suppressed to less than 3 pg/dl 
throughout the study in all subjects. Basal plasma renin activity was signifi- 
cantly lower in the patients as compared with controls (P<O.O5), and did not 
change in either group following metoclopramide. 
Basal aldosterone levels were not significantly different in patients as 
compared with controls, although patients did tend to have higher levels. The 
incremental and integrated response of aldosterone to metoclopramide in 
patients was significantly greater than controls (P < 0.01). The percentage 
increase in aldosterone was greater than controls in five of the six patients. 
Basal prolactin was higher in the patients than in the controls. All subjects 
had a significant rise in prolactin to metoclopramide (Px0.05). Five of six 
patients had an increased response of prolactin when compared to the controls 
and the four female patients had a significantly greater rise in prolactin as 
compared to the normals (P< 0.01). 
These data suggest that increased dopaminergic activity plays a compensa- 
tory role in inhibiting aldosterone secretion in patients with aldosteronism. It 
appears unlikely that a decrease of dopaminergic inhibition is involved in the 
pathogenesis of aldosteronism due to either adenoma or bilateral hyperplasia. 
Metoclopramide, a dopamine antagonist, acutely stimulates aldosterone secretion in 
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normal man (Norbiato et al., 1977). This action of metoclopramide can be blunted in a 
competitive dose-dependent fashion by preinfusion of dopamine (Noth et al., 1980; Carey 
et a/., 1980). Moreover, metoclopramide stimulates aldosterone secretion in hypo- 
pituitary and bilaterally nephrectomized man (Pratt et al., 1979). Metoclopramide has no 
effect on the metabolic clearance rate of aldosterone stimulating peptide (Brown et al., 
1979b). Metoclopramide also enhances the aldosterone output of zona glomerulosa cells 
from hyperplastic and adenomatous adrenal tissue in citro (Brown et al., 1979a). This 
evidence supports a direct stimulatory action of metoclopramide on aldosterone output 
of the adrenal zona glomerulosa. 
Both the presence and the absence of a response of plasma aldosterone to 
metoclopramide have been reported in patients with aldosteronism (Brown et al., 1979a; 
Bevilacqua et a/., 1980). To investigate whether metoclopramide indeed has an effect 
upon plasma aldosterone in hyperaldosteronism and whether dopamine is involved in the 
pathogenesis of hyperaldosteronism, we studied the aldosterone response to intravenous 
metoclopramide in six patients with hyperaldosteronism and in six normal subjects. 
METHODS 
After informed consent, all subjects were studied in the Clinical Research Center of the 
University of Michigan. Six patients with hyperaldosteronism were studied. This 
diagnosis was confirmed in each patient by measurement of 24-h urinary aldosterone, 
recumbent and upright plasma renin activity and plasma aldosterone under conditions of 
150 mEq and 10 mEq sodium diet. 
The six patients consisted of four women and two men. Three patients (two women and 
one man) had adrenal adenomata confirmed by bilateral adrenal venous aldosterone 
determination. Of these, one woman had an adenoma confirmed histologically. One man 
was presumed to have adenoma due to the high level of his aldosterone secretion and 
lateralization of uptake to the left on adrenal scintigraphy, but attempts to obtain right 
adrenal vein blood at adrenal vein catheterization were unsuccessful. Two female 
patients had bilateral adrenal hyperplasia. One woman had bilateral hypersecretion of 
aldosterone confirmed by adrenal vein catheterization and bilateral uptake on adrenal 
scintigraphy. The other patient’s diagnosis of hyperplasia was based upon the mildness of 
her abnormality in aldosterone secretion and early bilateral uptake on adrenal 
scintigraphy. The control group consisted of six normotensive normal male volunteers 
taking no medication. 
All subjects were studied on an ad libitum sodium diet. Prior to study, patients were 
withdrawn from all medications for at least 3 weeks, except for two patients who required 
x-methyldopa for severe hypertension. All patients were supplemented with oral 
potassium prior to the study. All patients and volunteers received dexamethasone (0.5 
mg) every 6 h for 72 h prior to study. The patients were supine and fasting from 2200 h the 
night prior to study. The normal controls were fasting from 2200 h and were supine for at 
least 1 h prior to the beginning of basal sampling. 
Blood samples were obtained through an indwelling catheter kept patent with a dilute 
heparinized saline solution. Blood for plasma aldosterone was obtained at  -60, -40, 
- 20,0, 15, 30,60,90, and 120 min. Plasma renin activity was obtained at 0, 30, and 120 
min. Plasma cortisol, serum sodium, and serum potassium were measured at  0, 60, and 
120 min. Serum prolactin levels were measured at 0 and 30 min. A single 10-mg dose of 
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metoclopramide was given intravenously at time zero. There were no side effects from the 
injection. 
Plasma aldosterone, plasma renin activity, and plasma cortisol were measured by 
radioimmunoassay (Antunes et al., 1976; Cohen ef al., 1971; Dash et al., 1975). Serum 
prolactin was measured by radioimmunoassay by the University of Michigan Ligand 
Assay Laboratory. Prolactin antiserum was obtained from Radioassay Systems Labora- 
tory, Inc., Carson, California, and prolactin substrate from Calbiochem-Behring Corp., 
La Jolla, California. Serum was incubated for 24 h with antiserum and then Iz5I labelled 
prolactin was added followed by another 24 h of incubation. Following this, separation 
was performed with sheep anti-rabbit globulin. Serum sodium and serum potassium were 
measured by Autoanalyzer. 
Statistical analysis was accomplished by use of the signed rank test within groups and 
two sample rank test between groups (Neter & Wasserman, 1974). Results are expressed 
as means k SEM. 
RESULTS 
There were no significant differences in basal sodium and potassium levels between 
patients and normals, although patients tended to have lower potassium levels. Serum 
sodium and potassium levels were unaltered after metoclopramide administration. 
Cortisol was less than 3 pg/dl throughout the study in all subjects, and was usually below 
the lower limits of detection of the assay (0.78 pg/dl). 
Basal plasma renin activity was significantly lower in the patients with hyperaldoster- 
onism as compared with normals (P < 0.05). There was no significant change in plasma 
renin activity following metoclopramide in either group (Table 1). 
Basal aldosterone did not differ significantly between the two groups, although patients 
had a higher mean basal level than normals (21 6 i 4.8 v. 6.2 k0-8 1 NS). Fig. 1 shows the 
aldosterone response to metoclopramide in the normals and patients with hyperaldoster- 
onism. Peak aldosterone levels occurred at 15 or 30 min following metoclopramide in all 
normals and all but one of the patients. The incremental response between basal and peak 
levels was significantly greater in the patients than in the normal controls (1 12.1 35.7 
ng/dl v. 1 1.2 2.6 ng/dl P < 0.01). The percentage change in aldosterone was greater in 
Table 1.  Plasma renin activity 
(ng/ml/h) in patients with aldoster- 
onism and in normals, basally and 
after rnetocloprarnide. Values repre- 
sent mean+SEM 
Plasma renin activity 
(ng/ml/h) 
Time Patients Normals 
0 0.45 k 0.23 * 1.85 k 0.4* 
30 0.47 k 0.23 1.72 k 0.24 
120 0.44k0.25 1.69k0.41 
* P < 0.05. 
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five of six patients than in any of the controls. One patient had a percentage change equal 
to the smallest percentage change in the normals. The mean percentage change for the 
patient group, therefore, approached but did not attain significance at  the P< 0.05 level 
when compared with the normals. Average values were 11 161442% for patients v. 
280 t 24% for normals. The integrated aldosterone response was significantly greater in 
the patients than in the normal controls (624.4 k 222.8 v. 40.9 
The basal prolactin was higher in patients than in controls; 59.6k44.3 ng/ml v. 
4.5k0.66 ng/ml (Pc0.01 two sample rank test, NS by t testing). Two patients had 
abnormally elevated basal levels. One male patient with presumed adrenal adenoma had a 
slightly elevated level of 30.7 ng/ml and one female patient with surgically documented 
adrenal adenoma had a level of 277.5 ng/ml. This patient is currently being investigated 
for the presence of a prolactinoma. Both of these patients were taking u-methyldopa at the 
time of the study. 
Fig. 2 illustrates the basal to peak (30 min) prolactin response to metoclopramide in 
both normals and patients with primary hyperaldosteronism. All subjects had a 
significant (P < 0.05) rise in serum prolactin following metoclopramide. All but one male 
patient had a greater rise in serum prolactin than the normals. The incremental response 
in all patients, however, approached but did not achieve significance at  P < 0.05. The 
incremental response was markedly greater in the four female patients v. the normal 
controls (P < 0.01). 
8.4; P < 0.01). 
DISCUSSION 
Evidence has recently accumulated that dopamine is involved in the control of 
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Fig. 1. Plasma aldosterone (ngidl) in (a) normals and (b) patients with hyperaldosteronism (- 
adenoma; - - - hyperplasia) before and after 10 mg metoclopramide given intravenously during 
dexamethasone suppression. Patients taking ?-methyldopa are designated with a. 
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Fig. 2. Basal to peak serum prolactin (ngiml) in (a) normals and (b) patients with hyperaldoster- 
onism (- adenoma; - - - hyperplasia) after 10 mg rnetoclopramide (i.v.). Patients taking 
a-methyldopa are designated with c(. 
aldosterone secretion in addition to angiotensin 11, potassium, and ACTH. Whitfield et al. 
(1980) have shown that in normals on a 50-mEq sodium diet the aldosterone response to 
upright posture was blunted by bromocriptine, a dopamine agonist, without concomitant 
change in plasma renin activity. The authors also reported that the angiotensin I1 
stimulated aldosterone response in these normals was suppressed by bromocriptine. 
Studies in vitro have shown that dopamine blunts the angiotensin I1 stimulated 
aldosterone response in isolated bovine adrenal glomerulosa cells. This effect was limited 
to the action of angiotensin I1 on the late phase of aldosterone secretion (McKenna et al., 
1979). Bromocriptine does not affect basal levels of aldosterone stimulated by chronic low 
sodium diet (Semple & Mason, 1978). This evidence supports a suppressive effect of 
dopamine on acute stimulatory responses of the adrenal zona giomerulosa in normals. 
Some evidence exists that secretion of dopamine is directly proportional to sodium 
intake, as urinary dopamine rises with intravenous saline loading in sodium deprived 
normals (Alexander et al., 1974). If there is an associated increase in dopamine levels in 
the adrenal, this may mediate a compensatory fall in aldosterone in response to saline 
loading. 
Investigations in patients with hyperaldosteronism have demonstrated that a dopa- 
minergic mechanism may also be active. Kuchel et al. (1980) reported that patients with 
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primary hyperaldosteronism have increased urinary and plasma dopamine levels. The rise 
in aldosterone produced by upright posture in two of these patients was accompanied by a 
decline in plasma dopamine levels; while one patient who failed to respond with a rise in 
aldosterone to upright posture had no change in plasma dopamine levels. These data 
suggest that dopamine also has an inhibitory role in the control of plasma aldosterone in 
patients with aldosteronism. 
In the present study, serum prolactin responses were used as a marker of the 
antidopaminergic action of metoclopramide. The higher basal prolactin levels observed 
in the patients could be due to the fact that four of the patients with higher basal prolactins 
than the normals were female (Molitch & Reichlin, 1980), and one male patient with a 
high basal prolactin level was taking r-methyldopa (Pettinger et d., 1963). Both of these 
factors could then cause the basal prolactin to be higher in the patients when compared 
with the normal male controls. In this study, the four female patients had a marked rise in 
prolactin as compared with the male controls ( P <  0-01). Females have previously been 
reported to have a somewhat greater response to metoclopramide than males, but this 
response did not achieve significance until 90 min after metoclopramide injection 
(Delitala et al., 1976). Also the reported levels achieved by normal females in that study 
were markedly lower than those seen in our female patients with aldosteronism (Delitala 
et al., 1976). Therefore, it seems unlikely that the observed difference in prolactin response 
can be explained by a difference in sex alone. This tendency to increased response of 
prolactin in the patients suggests increased pituitary dopaminergic inhibition. 
The basal levels of aldosterone were not significantly different between the patients and 
the normals. This is probably due to the suppressive effect of dexamethasone on basal 
plasma aldosterone. The dexamethasone treatment also may have contributed to the 
response to metoclopramide since dexamethasone has been shown to increase plasma 
dopamine levels in patients with primary hyperaldosteronism (Kuchel et al., 1980). 
From this study, it is clear that metoclopramide induced a marked rise in aldosterone 
levels in patients with hyperaldosteronism. The mechanism of this effect may be that in 
these patients the autonomous overproduction of aldosterone leads to sodium retention 
which then increases dopamine release. Further studies on urinary and plasma dopamine 
levels in patients with aldosteronism will be required to clarify this assumption. As in the 
normal state, sodium retention also suppresses the renin-angiotensin axis, but this 
suppression has little effect upon the overproduction of aldosterone by the adrenal glands 
of these patients. Therefore the inhibition of aldosterone secretion by dopamine may 
remain as a major modulator of plasma aldosterone levels. Blocking this inhibition with 
metoclopramide then markedly raises plasma aldosterone levels. A corollary to this effect 
is that it seems unlikely that a lack of dopaminergic inhibition is involved in the 
pathogenesis of hyperaldosteronism due to either adrenal adenoma or bilateral adrenal 
hyperplasia. 
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